Stockholm: When pharmacists across the Union ran short of common antibiotics and children’s fever syrups during recent winters, the episodes exposed an uncomfortable dependence: Europe had outsourced the manufacture of many of its most essential, least profitable medicines to a small number of factories, most of them in Asia. The Critical Medicines Act, on which the European Parliament and Council struck a provisional agreement in the early hours of 12 May, is the Union’s attempt to bring at least part of that production home.
The legislation targets a specific and stubborn category of failure. Drugs such as antibiotics, insulin, painkillers and saline solutions are clinically indispensable yet commercially marginal, sold at prices so low that manufacturers have little incentive to maintain spare capacity or hold buffer stocks. When a single plant falters, the shortage ripples across the continent. The Act seeks to change that calculus by rewarding security of supply, not merely lowest price, in the way medicines are procured and produced.
Its instruments are varied. Public procurement rules would be reshaped so that contracts can favour suppliers who manufacture within the Union or diversify their sourcing, rather than automatically awarding tenders to the cheapest bidder. Member states would be encouraged, and in some cases helped, to join forces and buy critical medicines collectively, pooling demand to give European producers the predictable orders that justify investment. And the legislation envisages support for new or expanded manufacturing of critical medicines and their active ingredients on European soil, the chemical building blocks that have migrated almost wholesale to a few overseas suppliers.
For a country like Sweden, with a small domestic market and a strong tradition of evidence-based health policy, the appeal is obvious but the caveats are sharp. Stockholm and its Nordic neighbours have long relied on cross-border cooperation to secure supplies that no single small state could guarantee alone, and joint procurement aligns neatly with that instinct. Yet Swedish officials and health economists have also been among the most vocal in warning that reshoring carries a price, and that paying more for domestically made medicines means money diverted from other corners of strained national health budgets.
That tension between resilience and cost runs through the entire file. Reshoring pharmaceutical production is expensive, slow and environmentally demanding, and there is no guarantee that European plants can match the scale that made Asian manufacturing so cheap in the first place. Industry groups have welcomed the political signal while pressing for financial commitments to match the ambition, noting that a preference for European supply means little if the funding to build and sustain that supply does not materialise.
The geopolitical backdrop gives the effort urgency. The same anxieties about strategic dependence that drive Europe’s debates on energy, defence and critical raw materials now extend to the medicine cabinet, with policymakers increasingly unwilling to leave the supply of life-saving drugs hostage to distant supply chains and the goodwill of exporting governments. The Act is, in that sense, a health measure wearing the clothes of industrial and security policy.
The provisional deal still requires formal endorsement by both institutions and the legal-linguistic revision that precedes adoption, so the real test lies ahead in implementation. Whether the Critical Medicines Act genuinely ends the recurring shortages that have alarmed patients and clinicians, or whether it founders on the gap between political ambition and the unglamorous economics of cheap generic drugs, will not be clear for years. What it already marks is a shift in how Europe thinks about medicine, no longer as a commodity to be bought wherever it is cheapest, but as infrastructure too important to leave to chance.
